Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Kiyohiko Takahashi  
Obihiro Kosei Hospital

Akinobu Nakamura (akinbo@tim.hi-ho.ne.jp)  
Hokkaido University  https://orcid.org/0000-0002-8192-0006

Sho Furusawa  
Obihiro Kosei Hospital

Kei Yokozeki  
Obihiro Kosei Hospital

Hajime Sugawara  
Obihiro Kosei Hospital

Hideyuki Yanagisawa  
Obihiro Kosei Hospital

Kazumasa Akikawa  
Obihiro Kosei Hospital

Hideaki Kikuchi  
Obihiro Kosei Hospital

Research

Keywords: Chronic kidney disease, Diabetic kidney disease, Normoalbuminuria, Sodium-glucose cotransporter 2 inhibitor

Posted Date: May 28th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-31068/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Version of Record: A version of this preprint was published at Journal of Clinical & Translational Endocrinology on December 1st, 2020. See the published version at https://doi.org/10.1016/j.jcte.2020.100244.
Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria

Kiyohiko Takahashi, Akinobu Nakamura, Sho Furusawa, Kei Yokozeki, Hajime Sugawara, Hideyuki Yanagisawa, Kazumasa Akikawa, and Hideaki Kikuchi

1 Third Department of Internal Medicine, Obihiro Kosei Hospital, Obihiro, Japan
2 Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Corresponding author: Akinobu Nakamura, M.D., Ph.D., Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

N-15, W-7, Kita-ku, Sapporo 060-8638, Japan
Tel: +81-11-706-5915
Fax: +81-11-706-7710
E-mail: akinbo@tim.hi-ho.ne.jp
Abstract

Background: We investigated the renoprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on renal function in patients with type 2 diabetes and chronic kidney disease (CKD) with normoalbuminuria.

Methods: A retrospective review of clinical records of Japanese participants with type 2 diabetes and CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m²) with normoalbuminuria (urine albumin to creatinine ratio < 30 mg/g Cr and/or urinary protein to creatinine ratio < 150 mg/g Cr) was conducted. Participants were categorized into two groups depending on whether they had started using SGLT2is. The main study outcome was a comparison of the change in renal function evaluated by eGFR after 1 year (ΔeGFR + 1 y) between the two groups. Then, we identified predictors that were associated with the outcome.

Results: Among the 48 participants, 21 were treated with SGLT2is (SGLT2 group) and 25 were treated with other antidiabetic medications (control group). Although eGFR was significantly decreased at 1 year in the control group, the decline in eGFR was not observed in the SGLT2 group. The change in eGFR was significantly greater in the SGLT2 group than in the control group (ΔeGFR + 1 year, -4.0 [-7.7 to -0.3] mL/min/1.73 m² in the control group, 0.9 [-3.9 to 5.7] mL/min/1.73 m² in the SGLT2 group).
group; \( P = 0.0231 \). Additionally, multiple linear regression analysis showed that an
initial dip was an independent factor associated with the worsening of renal function in
the SGLT2 group.

Conclusions: Although more favorable effects of SGLT2is on renal function were
observed in patients with type 2 diabetes and CKD with normoalbuminuria, the higher
initial dip was a possible marker of worsening renal function after the initiation of
SGLT2is.

Keywords: Chronic kidney disease, Diabetic kidney disease, Normoalbuminuria,
Sodium-glucose cotransporter 2 inhibitor
Background

The incidence and prevalence of diabetes are increasing worldwide, and the ultimate goal of treating diabetes is to prevent or delay the progression of microvascular and macrovascular complications. Dialysis resulting from diabetes is extremely prevalent in Japan [1]. In 2017, the number of patients on chronic dialysis reached 334,505 [1]. Traditionally, it has been thought that typical diabetic nephropathy progresses from normal albuminuria to micro/macroalbuminuria and gradually to decreases in renal function. However, recently, it has been shown that there are atypical diabetic nephropathy cases that already exhibit reduced renal function without micro/macroalbuminuria. Therefore, diabetic kidney disease was proposed as a condition that includes typical and atypical diabetic nephropathy [2]. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) improve glucose tolerance by suppressing renal glucose reabsorption without direct pharmacological action on pancreatic beta cells. Four large prospective clinical trials have shown that SGLT2is decrease the composition renal endpoints such as decline in estimated glomerular filtration rate (eGFR), doubling of the serum creatinine level, new end-stage kidney disease, death from renal or cardiovascular causes, or progression to macroalbuminuria [3-6]. In addition, it has been reported that, in patients with type 2 diabetes and chronic
kidney disease (CKD), SGLT2is prevent the decline in eGFR [7-10]. However, studies on the effects of SGLT2is on renal function in patients with type 2 diabetes and CKD with normoalbuminuria remain limited [8, 9].

In the present study, we investigated the renoprotective effects of SGLT2is on renal function in patients with type 2 diabetes and CKD with normoalbuminuria and identified predictors that were associated with the outcome.
Methods

Study design and participants

The major inclusion criteria were type 2 diabetes and CKD (eGFR < 60 mL/min/1.73 m$^2$) with normoalbuminuria (urine albumin to creatinine ratio [UACR] < 30 mg/g Cr and/or urinary protein to creatinine ratio [UPCR] < 150 mg/g Cr) at SGLT2is initiation. As a control, patients who were not administered SGLT2is were also included. The exclusion criteria were as follows: type 1 diabetes, use of glucagon-like peptide-1 receptor agonists for type 2 diabetes, endocrine disease, use of steroids or immunosuppressants for autoimmune disease, dialysis, transplantation, liver cirrhosis, and malignancy. Finally, 46 patients were eligible for evaluation. The study was conducted with the approval of the Institutional Review Board of Obihiro Kosei Hospital (2020-017), and registered with the University Hospital Medical Information Network (UMIN; number UMIN000040424).

Study definitions and outcomes

We conducted a retrospective review of the clinical records of all consecutive Japanese outpatients with type 2 diabetes admitted to Obihiro Kosei Hospital in Obihiro from April 2014 to December 2019. The participants were categorized into two groups
depending on whether they used SGLT2is: in the SGLT2 group, patients started receiving SGLT2is in addition to their other antidiabetic medication; and in the control group, patients received conventional antidiabetic medications alone. Outcome data were collected from the patients’ medical records. Baseline data for age, sex, duration of diabetes, and medications for diabetes and hypertension were also collected. Common measurements, such as body weight, body mass index (BMI), systolic and diastolic blood pressure (SBP and DBP, respectively), plasma glucose (PG) level, glycated hemoglobin (HbA1c) level, kidney and liver function test results, high-density lipoprotein cholesterol (HDL) level, low-density lipoprotein (LDL) level, triglyceride (TG) level, UACR, and/or UPCR, at each clinic visit were collected. The eGFR 1–2 months after SGLT2is initiation was also used as an eGFR initial data point. We defined the change in eGFR as the initial dip, as previously reported [7, 10, 11]. These parameters were measured using commercially available assay kits.

The primary objective of this study was to assess the clinical effectiveness of SGLT2is on renal function by analyzing the change in eGFR at one year (ΔGFR + 1 y) after initiating SGLT2is, compared with the change after conventional antidiabetic medication. The secondary objective was to investigate the variables associated with ΔGFR + 1 y, to identify suitable patients with type 2 diabetes for the renoprotective
effect of SGLT2is. The initial dip and $\Delta GFR + 1 \text{ y}$ were calculated as follows: initial
dip = eGFR at 1 or 2 months after starting SGLT2is − eGFR at the start of SGLT2is;
$\Delta GFR + 1 \text{ y} = eGFR$ at 1 year − eGFR at baseline.

Statistical analysis

Chi-square test, Mann-Whitney $U$-test, unpaired $t$-test, or paired $t$-test was used to
compare between the two groups as appropriate. Results are shown as mean ± standard
deviation or median. We used a two-way analysis of variance (ANOVA) followed by
post hoc Bonferroni test for repeated measurements. Calculations for correlation
coefficients and simple linear regression analyses were performed to test for
associations between $\Delta GFR + 1 \text{ y}$ and baseline parameters in the SGLT2 group.
Additionally, we performed stepwise multivariate regression analysis to examine which
factors independently determined $\Delta GFR+1\text{y}$ in the SGLT2 group. $P$-values < 0.05 were
considered statistically significant. Statistical analyses were performed using JMP 14
(SAS Inc., Cary, NC, USA) and Microsoft Excel Statistics 2012 for Windows (SSRI
Co. Ltd, Tokyo, Japan).
Results

Table 1 shows the underlying diseases present in study patients. Of the 46 patients, the SGLT2 group comprised 21 patients, and the control group comprised 25 patients. There were no differences in most of the baseline parameters between the two groups, except for duration of diabetes, PG, HbA1c, alanine aminotransferase (ALT), or TG. The number of patients with CKD staging among both groups was as follows: SGLT2 group G3a: 15, G3b: 5, and G4: 1; control group G3a: 18, G3b: 5, and G4: 2. As shown in Fig. 1, the eGFR in the control group was significantly decreased after 1 year. However, there was no decrease in eGFR in the SGLT2 group. As shown in Fig. 2, the magnitude of the effect for eGFR was significantly greater in the SGLT2 group than in the control group ($\Delta eGFR + 1\text{ year}$: -4.0 (-7.7 to -0.3) mL/min/1.73 m$^2$ in the control group, 0.9 (-3.9 to 5.7) mL/min/1.73 m$^2$ in the SGLT2 group; $P = 0.0231$). Next, to reveal the factors associated with the changes in eGFR at 1 year after starting SGLT2is, we examined the correlations between $\Delta eGFR + 1\text{ year}$ and the clinical parameters in the SGLT2 group. As shown in Table 2, only the initial dip showed a significant positive correlation ($P = 0.0159$) with $\Delta eGFR + 1\text{ year}$. Moreover, as shown in Table 3, multiple linear regression analysis identified higher initial dip as an independent factor associated with worsening of renal function in the SGLT2 group, after adjusting for age,
BMI, HbA1c level, and eGFR ($P = 0.0166$).
Discussion

In the present study, we showed that additional treatment with SGLT2is prevents the decline in eGFR in the SGLT2 group compared with that in the control group. Although we had previously shown that more favorable effects of SGLT2is on renal function in patients with type 2 diabetes and CKD with normoalbuminuria compared with patients with macroalbuminuria [9], this study did not include a control group. Therefore, this study was able to confirm the renoprotective effects on SGLT2is for patients with type 2 diabetes and CKD with normoalbuminuria compared with non-SGLT2is user.

In addition, using multiple linear regression analysis we showed that the initial dip in the SGLT2 group was useful in predicting the renoprotective effect of SGLT2is. Previously, Miyoshi et al. showed that the decline in eGFR before starting SGLT2is in patients with type 2 diabetes and CKD stages 3-4 was an independent factor associated with renal function outcomes [7]. However, there have been no studies on the predictive factors associated with the worsening of renal function in patients with type 2 diabetes and CKD with normoalbuminuria. This is the first report to identify independent factors associated with the worsening of renal function in patients with type 2 diabetes and CKD with normoalbuminuria.

It has been proposed that one mechanism for the renoprotective effects of SGLT2is
is decreasing intraglomerular pressure through tubuloglomerular feedback restoration [12-15]. It has also been reported that empagliflozin reduces the intraglomerular pressure to 6–8 mmHg in patients with type 1 diabetes [16]. In fact, a decrease in eGFR is typically observed within 1 month after initiating SGLT2is therapy [3]. This phenomenon is called the initial dip or initial drop [17]. As other mechanisms, SGLT2is have the renoprotective effect through not only their anti-inflammatory and anti-oxidative stress effects [18, 19], but also increase of hematocrit and β-hydroxybutyrate [15].

Pathological findings revealed that tubulointerstitial and vascular lesions were more advanced in patients with type 2 diabetes and CKD with normoalbuminuria than in those with micro/macroalbuminuria [20]. In contrast, glomerular lesions were more advanced in patients with type 2 diabetes and CKD with micro/macroalbuminuria than in those with normoalbuminuria [20]. Previously, it has been shown that the pathological findings in patients with type 2 diabetes and CKD with normoalbuminuria are similar to those in patients with nephrosclerosis [21]. In nephrosclerosis, it is thought that the glomeruli undergo progressive ischemic changes [22], in which intraglomerular pressure can be normal or decreased [23]. Results from the EMPA-REG outcome study demonstrated that the eGFR increases after withdrawing SGLT2i [3].
These data support the idea that the initial dip in GFR after SGLT2is administration is a hemodynamic effect [3]. It seems likely that some patients with type 2 diabetes and CKD with normoalbuminuria who show a high initial dip after SGLT2is initiation have reduced renoprotective effects due to an excessive drop in intraglomerular pressure caused by changes in blood volume or renal perfusion. Future studies will determine whether this result can also be applied to patients with type 2 diabetes and CKD with micro/macroalbuminuria with glomerular lesions.

There are some limitations to the present study. First, this study was retrospective in nature. Second, the sample size was small, which might have limited its statistical power. Third, baseline parameters such as the duration of diabetes, PG levels, and HbA1c levels were unbalanced between the groups, which may have made interpretation difficult. Fourth, this study had a short follow-up period and was conducted in a single center. Larger and longer prospective studies will be required to verify our results in the future.

In conclusion, our study suggests that renoprotective effects of SGLT2is on renal function were observed in patients with type 2 diabetes with CKD and normoalbuminuria. Additionally, patients who show a high initial dip after SGLT2is initiation should be carefully monitored for decline in renal function.
Abbreviations

ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin II receptor blocker; AST, aspartate aminotransferase; BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; PG, plasma glucose; SBP, systolic blood pressure; SGLT2is, sodium-glucose cotransporter 2 inhibitors; TG, triglyceride; UACR, urinary albumin-to-creatinine ratio; UPCR, urinary protein to creatinine ratio.

Declarations

Ethics approval and consent to participate: This study was conducted with approval from the Institutional Review Board of the Obihiro Kosei Hospital (2020-017), and registered with the University Hospital Medical Information Network (UMIN; number UMIN000040424).

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: AN has obtained research support from Mitsubishi Tanabe
Pharma, Daiichi Sankyo, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, LifeScan Japan, Nippon Boehringer Ingelheim, and Taisho Pharmaceutical.

**Funding:** This study was not supported by any institution.

**Authors’ contributions:** KT and AN contributed to writing the manuscript. KT and SF contributed to data analysis. KT, AN, and SF contributed to the discussion, and reviewed and edited the manuscript. KT is the guarantor of this work and, as such, had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. All authors have read and approved the final manuscript.

**Acknowledgments:** We thank the participants at Obihiro Kosei Hospital.
References

1. Nitta K, Masakane I, Hanafusa N, et al. Annual dialysis data report 2017, JSDT renal data registry. Ren Replace Ther. 2019; 5: 1-44.

2. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37: 2864-83.

3. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323-34.

4. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644-57.

5. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-57.

6. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295-306.

7. Miyoshi H, Kameda H, Yamashita K, et al. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabetes Investig. 2019; 10: 1510-7.

8. Sugiyama S, Jinnouchi H, Yoshida A, et al. Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b-4: a real world report from a Japanese specialized diabetes care center. J Clin Med Res. 2019; 11: 267-74.

9. Nakamura A, Miyoshi H, Kameda H, et al. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. Diabetol Metab Syndr. 2020; 12: 4.

10. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013; 15: 463-73.

11. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-97.

12. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44: 375-93.
13. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014; 13: 28.

14. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014; 129: 542-4.

15. Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications. 2018; 32: 720-5.

16. Skrtic M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014; 57: 2599-602.

17. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017; 60: 215-25.

18. Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018; 20: 1988-93.

19. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, A highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016; 48: 191-5.

20. Shimizu M, Furuichi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013; 36: 3655-62.

21. Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 2008; 17: 266-70.

22. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens. 1997; 15: 1365-77.

23. Abe M, Soma M. Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection. Hypertens Res. 2015; 38: 804-6.
Changes in eGFR in patients with or without SGLT2is administration. Data are presented as mean ± standard deviation (SD). **P < 0.01: two-way analysis of variance followed by post hoc Bonferroni test, 0 year vs. 1 year in the control group. eGFR, estimated glomerular filtration rate; SGLT2is, sodium-glucose cotransporter 2 inhibitors.

Comparison of changes in eGFR in patients with or without SGLT2is administration. The Wilcoxon rank-sum test was used for statistical analysis. *P < 0.05, eGFR, estimated glomerular filtration rate; SGLT2is, sodium-glucose cotransporter 2 inhibitors.
|                               | Control (n=25) | SGLT2 (n=21) | P value |
|--------------------------------|----------------|--------------|---------|
| **Age (years)**                | 67.9 ± 9.1     | 67.4 ± 7.9   | 0.8333  |
| **Man/Woman (n)**              | 12/13          | 11/10        | 0.7672  |
| **Duration of diabetes (years)**| 7.0 (2.0 to 13.5) | 12.5 (7.3 to 24.0) | 0.0429 |
| **Weight (kg)**                | 65.3 ± 14.5    | 69.9 ± 12.1  | 0.2810  |
| **BMI (kg/m²)**                | 25.5 ± 4.2     | 27.9 ± 4.7   | 0.0967  |
| **PG (mg/dl)**                 | 146.8 ± 47.4   | 206.1 ± 79.6 | 0.0032  |
| **HbA1c (%)**                  | 7.1 ± 1.0      | 8.0 ± 1.1    | 0.0058  |
| **eGFR (mL/min/1.73 m²)**      | 49.3 ± 10.9    | 49.7 ± 9.1   | 0.9014  |
| **AST (U/L)**                  | 22.0 (18.5 to 28.0) | 26.0 (20.0 to 42.0) | 0.0898 |
| **ALT (U/L)**                  | 23.0 (13.0 to 30.0) | 29.0 (20.0 to 38.0) | 0.0310 |
| **HDL (mg/dl)**                | 45.1 ± 13.0    | 49.7 ± 15.1  | 0.2875  |
| **LDL (mg/dl)**                | 109.7 ± 33.4   | 106.1 ± 26.2 | 0.6995  |
| **TG (mg/dl)**                 | 170.5 (126.3 to 222.8) | 121.0 (92.0 to 163.5) | 0.0224 |
| **Stage of diabetic nephropathy**| III 23/ IV 2 | III 20/ IV 1 | 0.6577  |
| **Chronic kidney disease**     | IIIa 18/IIIb 5/ IV 2 | IIIa 15/ IIIb 5/ IV 1 | 0.8780  |
| **UACR (mg/g Cr)**             | 13.0 (7.3 to 16.9) | 12.6 (8.0 to 16.5) | 0.8838  |
| **UPCR (mg/g Cr) (n = 1 and 4)**| 50.8 | 115.21 ± 21.7 | - |
| **SBP (mmHg)**                 | 126.3 ± 22.0   | 127.2 ± 10.8 | 0.9058  |
| **DBP (mmHg)**                 | 73.5 ± 14.5    | 70.91 ± 9.1  | 0.6085  |
| **Treatment with ARB or ACEI (%)** | 56.0 | 47.6 | 0.5708 |
| **Diuretics (%)**              | 24.0           | 14.3         | 0.4081  |
| **SGLT2i (%)**                 |                |              |         |
| Empagliflozin                  | 0              | 28.6         |         |
| Ipragliflozin                  | 0              | 14.3         |         |
| Luseogliflozin                 | 0              | 0            |         |
| Dapagliflozin                  | 0              | 19.1         |         |
| Tofogliflozin                  | 0              | 0            |         |
| Canagliflozin                  | 0              | 38.1         |         |
| **Antidiabetic drugs (%)**     |                |              |         |
| Sulfonylureas (%)              | 16.0           | 4.8          | 0.2226  |
| Metformin (%)                  | 32.0           | 33.3         | 0.9235  |
| Thiazolidinedione (%)          | 0              | 0            | -       |
| Alpha-glucosidase inhibitor (%)| 4.0            | 23.8         | 0.0469  |
| Glinide (%)                    | 8.0            | 19.1         | 0.2678  |
Dipeptidyl peptidase-4 inhibitor (%)  84.0  71.4  0.3032
Insulin (%)  24.0  28.6  0.7251
Glucagon like peptide-1 receptor agonist (%)  0  0  -

Values are shown as means ± standard deviation, median, n, or %.

SGLT2, sodium-glucose cotransporter 2; BMI, body mass index; PG, plasma glucose; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; TG, triglyceride; UACR, urine albumin-to-creatinine ratio; UPCR, urinary protein to creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
Table 2. Relationship between ΔeGFR + 1 y and baseline parameters examined in SGLT2 group

| Parameter                        | Correlation coefficient | P value |
|----------------------------------|-------------------------|---------|
| Duration of diabetes (years)     | 0.1701                  | 0.4735  |
| Age (years)                      | −0.0839                 | 0.7178  |
| Weight (kg)                      | −0.2120                 | 0.3983  |
| BMI (kg/m^2)                     | −0.2047                 | 0.4153  |
| PG (mg/dl)                       | 0.0562                  | 0.8089  |
| HbA1c (%)                        | 0.2048                  | 0.3731  |
| eGFR (mL/min/1.73 m^2)           | −0.1697                 | 0.4621  |
| initial dip (mL/min/1.73 m^2)    | 0.5448                  | 0.0159  |
| AST (U/L)                        | 0.1409                  | 0.5649  |
| ALT (U/L)                        | 0.0723                  | 0.7688  |
| HDL (mg/dL)                      | −0.1405                 | 0.5436  |
| LDL (mg/dL)                      | 0.2012                  | 0.4089  |
| TG (mg/dL)                       | 0.1953                  | 0.3963  |
| UACR (mg/g Cr)                   | −0.3991                 | 0.0813  |
| SBP (mmHg)                       | 0.5605                  | 0.0729  |
| DBP (mmHg)                       | 0.4721                  | 0.1426  |

ΔeGFR + 1 y, the change in estimated glomerular filtration rate at one year after starting sodium-glucose cotransporter 2 inhibitor; SGLT2, sodium-glucose cotransporter 2; BMI, body mass index; PG, plasma glucose; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; TG, triglyceride; UACR, urine albumin to creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 3. Multiple regression analysis for ΔeGFR + 1 y and baseline parameters in the SGLT2 group

| Standardized partial regression coefficient | $P$ value |
|---------------------------------------------|-----------|
| Initial dip (mL/min/1.73 m$^2$)             | 0.7073    |
|                                             | 0.0166    |

$R^2=0.2793$. A multiple regression with stepwise selection was performed considering age, BMI, HbA1c, eGFR, and initial dip. $ΔeGFR + 1 \text{ y}$, the change in estimated glomerular filtration rate one year after starting sodium-glucose cotransporter 2 inhibitor; SGLT2, sodium-glucose cotransporter 2; BMI, body mass index; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate.
Figures

Figure 1

Changes in eGFR in patients with or without SGLT2is administration. Data are presented as mean ± standard deviation (SD). **P < 0.01: two-way analysis of variance followed by post hoc Bonferroni test, 0 year vs. 1 year in the control group. eGFR, estimated glomerular filtration rate; SGLT2is, sodium-glucose cotransporter 2 inhibitors.
Figure 2

Comparison of changes in eGFR in patients with or without SGLT2is administration. The Wilcoxon rank-sum test was used for statistical analysis. *P < 0.05. eGFR, estimated glomerular filtration rate; SGLT2is, sodium-glucose cotransporter 2 inhibitors.